<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mimmun</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская иммунология</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Immunology (Russia)</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1563-0625</issn><issn pub-type="epub">2313-741X</issn><publisher><publisher-name>SPb RAACI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15789/1563-0625-2019-5-945-952</article-id><article-id custom-type="elpub" pub-id-type="custom">mimmun-1617</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КРАТКИЕ СООБЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SHORT COMMUNICATIONS</subject></subj-group></article-categories><title-group><article-title>ЭКСПРЕССИЯ Toll-ПОДОБНЫХ РЕЦЕПТОРОВ TLR2, TLR3, TLR4 И ПРОВОСПАЛИТЕЛЬНЫХ ЦИТОКИНОВ TNF И IL-6 В БИОПТАТАХ ПАЦИЕНТОВ С НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНЬЮ ПЕЧЕНИ</article-title><trans-title-group xml:lang="en"><trans-title>EXPRESSION OF TLR2, TLR3, TLR4 AND PROINFLAMMATORY TNF AND IL-6 CYTOKINES IN LIVER BIOPSIES OF NONALCOHOLIC FATTY LIVER DISEASE PATIENTS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Боголюбова</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogolyubova</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Боголюбова Аполлинария Васильевна, младший научный сотрудник лаборатории передачи внутриклеточных сигналов в норме и патологии</p><p>119991, Россия, Москва, ул. Вавилова, 32.</p><p>Тел.: 8 (499) 135-99-64. Факс: 8 (499) 135-14-05.</p></bio><bio xml:lang="en"><p>Bogolyubova Apollinariya V., Junior Research Associate, Laboratory of Intracellular Signaling in Health and Disease</p><p>119991, Russian Federation, Moscow, Vavilova str., 32.</p><p>Phone: 7 (499) 135-99-64. Fax: 7 (499) 135-14-05.</p></bio><email xlink:type="simple">apollinariya.bogolyubova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мишина</surname><given-names>Е. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Mishina</surname><given-names>E. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>научный сотрудник отдела прогнозирования и инноваций диабета</p></bio><bio xml:lang="en"><p>Research Associate, Department of Prediction and Innovations in Diabetes</p></bio><email xlink:type="simple">xxx@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богомолов</surname><given-names>П. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogomolov</surname><given-names>P. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., профессор, руководитель отдела гепатологии</p></bio><bio xml:lang="en"><p>PhD (Medicine), Head, Department of Hepatology</p><p>Moscow </p></bio><email xlink:type="simple">xxx@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мациевич</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Matsievich</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., заведующая отделением гастроэнтерологии</p></bio><bio xml:lang="en"><p>PhD (Medicine), Head, Department of Gastroenterology</p></bio><email xlink:type="simple">xxx@mail.ru</email><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кокина</surname><given-names>К. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kokina</surname><given-names>K. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>научный сотрудник отдела гепатологии</p></bio><bio xml:lang="en"><p>Research Associate, Department of Hepatology</p></bio><email xlink:type="simple">xxx@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Майоров</surname><given-names>А. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Mayorov</surname><given-names>A. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., заведующий отделом прогнозирования и инноваций диабета </p><p>Москва</p></bio><bio xml:lang="en"><p>PhD, MD (Medicine), Head, Department of Prediction and Innovations in Diabetes</p></bio><email xlink:type="simple">xxx@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белоусов</surname><given-names>П. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Belousov</surname><given-names>P. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>младший научный сотрудник лаборатории передачи внутриклеточных сигналов в норме и патологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Junior Research Associate, Laboratory of Intracellular Signaling in Health and Disease</p><p>Moscow</p></bio><email xlink:type="simple">xxx@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУН «Институт молекулярной биологии имени В.А. Энгельгардта» Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Министерства здравоохранения РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Endocrinology Research Centre, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ГБУЗ МО «Московский областной научно-исследовательский клинический институт имени М.Ф. Владимирского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Moscow Regional M. Vladimirsky Research and Clinical Institute</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ООО «Клиническая больница Центросоюза РФ»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>LTD “Clinical Hospital of Russian Central Union”, Moscow</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>11</day><month>03</month><year>2019</year></pub-date><volume>21</volume><issue>5</issue><fpage>945</fpage><lpage>952</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Боголюбова А.В., Мишина Е.Е., Богомолов П.О., Мациевич М.В., Кокина К.Ю., Майоров А.Ю., Белоусов П.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Боголюбова А.В., Мишина Е.Е., Богомолов П.О., Мациевич М.В., Кокина К.Ю., Майоров А.Ю., Белоусов П.В.</copyright-holder><copyright-holder xml:lang="en">Bogolyubova A.V., Mishina E.E., Bogomolov P.O., Matsievich M.V., Kokina K.Y., Mayorov A.Y., Belousov P.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.mimmun.ru/mimmun/article/view/2019-21-5-12">https://www.mimmun.ru/mimmun/article/view/2019-21-5-12</self-uri><abstract><p>Неалкогольная жировая болезнь печени (НАЖБП) представляет собой группу тесно ассоциированных с ожирением заболеваний, являющихся одними из наиболее распространенных и социально значимых патологий печени в современном западном мире. Возникновение и прогрессия НАЖБП от простого стеатоза в неалкогольный стеатогепатит с последующим развитием фиброза являются ведущими факторами в патогенезе значительной части случаев наиболее тяжелых патологий печени, таких как цирроз и печеночно-клеточный рак, а также внепеченочных метаболических осложнений НАЖБП, таких как инсулинорезистентность и сахарный диабет 2 типа. Воспалительный компонент является важнейшим фактором патогенеза НАЖБП, в частности в рамках прогрессии простого стеатоза в неалкогольный стеатогепатит (НАСГ). Вместе с тем роль важнейших медиаторов воспалительного ответа – рецепторов врожденного иммунитета, в частности Toll-подобных рецепторов, в патогенезе НАЖБП изучена крайне фрагментарно. В представленной работе мы при помощи биоинформатического анализа находящихся в публичном доступе баз данных экспрессионных профилей выявили, что из всех Toll-подобных рецепторов в нормальной ткани печени человека на достаточно высоком уровне экспрессируются только Toll-подобные рецепторы TLR1, TLR2, TLR3 и TLR4, экспрессия мРНК трех из которых (TLR2, TLR3 и TLR4), а также важнейших медиаторов иммунного ответа провоспалительных цитокинов фактора некроза опухоли (TNF) и интерлейкина-6 (IL-6) была далее проанализирована нами при помощи ПЦР с обратной транскрипцией в биоптатах печени 20 пациентов с НАЖБП (стеатоз, n = 10; неалкогольный стеатогепатит, n = 10), а также 4 пациентов с клиническим подозрением на НАЖБП, у которых, однако, в биоптатах печени отсутствовали гистологические признаки НАЖБП. Нами было обнаружено значительное увеличение экспрессии мРНК TLR2, TLR3 и TLR4 в биоптатах печени пациентов с НАСГ по сравнению с контрольной выборкой пациентов без гистологических признаков НАЖБП. Также была показана ассоциация уровня экспрессии мРНК данных рецепторов со степенью повреждения печени по данным гистологического анализа (уровень стеатоза и баллонной дистрофии гепатоцитов), а также с концентрацией в плазме крови пациентов мочевой кислоты, важнейшего эндогенного стимулятора врожденного иммунитета. Полученные нами данные указывают на возможную вовлеченность врожденного иммунитета, а именно Toll-подобных рецепторов, в патогенез НАЖБП.</p></abstract><trans-abstract xml:lang="en"><p>Non-alcoholic fatty liver disease (NAFLD) is a group of conditions closely associated with obesity that are among the most common and socially significant liver diseases in the modern Western world. The emergence and progression of NAFLD from simple steatosis to non-alcoholic steatohepatitis with the subsequent development of fibrosis are the leading factors in the pathogenesis of a significant proportion of the most severe liver pathologies, such as cirrhosis and hepatocellular carcinoma, as well as extrahepatic metabolic complications of NAFLD, such as insulin resistance and type 2 diabetes mellitus. The inflammatory component is one of the most important factors in the pathogenesis of NAFLD, particularly in the context of the progression of simple steatosis to non-alcoholic steatohepatitis. At the same time, the role of the most important mediators of the inflammatory response, innate immunity receptors and the Toll-like receptors in particular, in the pathogenesis of NAFLD has been poorly studied. In the present work, we first used the bioinformatics analysis of the publicly available gene expression databases to demonstrate that only TLR1, TLR2, TLR3 and TLR4 were significantly expressed in the healthy human liver. We then used the reverse transcription PCR to measure the mRNA expression levels of TLR2, TLR3, and TLR4, as well as those of the important pro-inflammatory mediators tumor necrosis factor (TNF) and interleukin-6 (IL-6), in the liver biopsy specimens obtained from 20 patients with NAFLD (simple steatosis, n = 10; non-alcoholic steatohepatitis, n = 10), as well as from 4 obese patients with clinical suspicion for NAFLD but no histological signs of NAFLD in their liver biopsies. We found a significant increase in the expression of TLR2, TLR3 and TLR4 mRNA in liver biopsy samples obtained from patients with non-alcoholic steatohepatitis as compared to those obtained from controls without histological signs of NAFLD. We were also able to demonstrate the association between the hepatic levels of TLR2, TLR3 and TLR4 mRNAs with the histological degree of liver damage as evidenced by the degree of steatosis and balloon dystrophy of hepatocytes, as well as with the plasma levels of uric acid, the important endogenous stimulator of innate immunity. Our data indicate the possible involvement of innate immunity, particularly the Toll-like receptors, in the pathogenesis of NAFLD.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Toll-подобные рецепторы</kwd><kwd>провоспалительные цитокины</kwd><kwd>неалкогольная жировая болезнь печени</kwd><kwd>неалкогольный стеатогепатит</kwd><kwd>стеатоз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Toll-like receptors</kwd><kwd>proinflammatory cytokines</kwd><kwd>nonalcoholic fatty liver disease</kwd><kwd>nonalcoholic steatohepatitis</kwd><kwd>steatosis</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Результаты исследований экспрессии Toll-подобных рецепторов получены за счет средств Российского научного фонда (грант 17-15-01475). Экспрессия провоспалительных цитокинов была изучена в рамках Программы фундаментальных исследований государственных академий наук на 2013-2020 годы (тема № 01201363822).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Benedict M., Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol., 2017, Vol. 9, no. 16, pp. 715-732.</mixed-citation><mixed-citation xml:lang="en">Benedict M., Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol., 2017, Vol. 9, no. 16, pp. 715-732.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Ghaemi-Oskouie F., Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr. Rheumat. Rep., 2011, Vol. 13, no. 2, pp. 160-166.</mixed-citation><mixed-citation xml:lang="en">Ghaemi-Oskouie F., Shi Y. The role of uric acid as an endogenous danger signal in immunity and inflammation. Curr. Rheumat. Rep., 2011, Vol. 13, no. 2, pp. 160-166.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kanuri G., Ladurner R., Skibovskaya J., Spruss A., Königsrainer A., Bischoff S.C., Bergheim I. Expression of Toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int., 2015, Vol. 35, no. 2, pp. 562-568.</mixed-citation><mixed-citation xml:lang="en">Kanuri G., Ladurner R., Skibovskaya J., Spruss A., Königsrainer A., Bischoff S.C., Bergheim I. Expression of Toll-like receptors 1-5 but not TLR 6-10 is elevated in livers of patients with non-alcoholic fatty liver disease. Liver Int., 2015, Vol. 35, no. 2, pp. 562-568.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kawasaki T. and Kawai T. Toll-like Receptor signaling pathways. Front. Immunol., 2014, Vol. 5, p. 461.</mixed-citation><mixed-citation xml:lang="en">Kawasaki T. and Kawai T. Toll-like Receptor signaling pathways. Front. Immunol., 2014, Vol. 5, p. 461.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Kiziltas S., Ata P., Colak Y., Mesçi B., Senates E., Enc F., Ulasoglu C., Tuncer I., Oguz A. TLR4 gene polymorphism in patients with nonalcoholic fatty liver disease in comparison to healthy controls. Metab. Syndr. Relat. Disord., 2014, Vol. 12, no. 3, pp. 165-170.</mixed-citation><mixed-citation xml:lang="en">Kiziltas S., Ata P., Colak Y., Mesçi B., Senates E., Enc F., Ulasoglu C., Tuncer I., Oguz A. TLR4 gene polymorphism in patients with nonalcoholic fatty liver disease in comparison to healthy controls. Metab. Syndr. Relat. Disord., 2014, Vol. 12, no. 3, pp. 165-170.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Liu H., Li J., Tillman B., Morgan T.R., French B.A., French S.W. TLR3/4 Signaling is mediated via the NFκB-CXCR4/7 pathway in human alcoholic hepatitis and non-alcoholic steatohepatitis which formed mallory-denk bodies. Exp. Mol. Pathol., 2014, Vol. 97, no. 2, pp. 234-240.</mixed-citation><mixed-citation xml:lang="en">Liu H., Li J., Tillman B., Morgan T.R., French B.A., French S.W. TLR3/4 Signaling is mediated via the NFκB-CXCR4/7 pathway in human alcoholic hepatitis and non-alcoholic steatohepatitis which formed mallory-denk bodies. Exp. Mol. Pathol., 2014, Vol. 97, no. 2, pp. 234-240.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Miura K., Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J. Gastroenterol., 2014, Vol. 20, no. 23, pp. 7381-7391.</mixed-citation><mixed-citation xml:lang="en">Miura K., Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J. Gastroenterol., 2014, Vol. 20, no. 23, pp. 7381-7391.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Miura K., Seki E., Ohnishi H., Brenner D.A. Role of Toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol. Res. Pract., 2010, Vol. 2010, 362847. doi: 10.1155/2010/362847.</mixed-citation><mixed-citation xml:lang="en">Miura K., Seki E., Ohnishi H., Brenner D.A. Role of Toll-like receptors and their downstream molecules in the development of nonalcoholic fatty liver disease. Gastroenterol. Res. Pract., 2010, Vol. 2010, 362847. doi: 10.1155/2010/362847.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">du Plessis J., Korf H., van Pelt J., Windmolders P., Vander Elst I., Verrijken A., Hubens G., van Gaal L., Cassiman D., Nevens F., Francque S., van der Merwe S. Pro-inflammatory cytokines but not endotoxin-related parameters associate with disease severity in patients with NAFLD. PLoS ONE, 2016, Vol. 11, no. 12, e0166048. doi: 10.1371/journal.pone.0166048.</mixed-citation><mixed-citation xml:lang="en">du Plessis J., Korf H., van Pelt J., Windmolders P., Vander Elst I., Verrijken A., Hubens G., van Gaal L., Cassiman D., Nevens F., Francque S., van der Merwe S. Pro-inflammatory cytokines but not endotoxin-related parameters associate with disease severity in patients with NAFLD. PLoS ONE, 2016, Vol. 11, no. 12, e0166048. doi: 10.1371/journal.pone.0166048.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sharifnia T., Antoun J., Verriere T.G., Suarez G., Wattacheril J., Wilson K.T., Peek R.M. Jr, Abumrad N.N., Flynn C.R. Hepatic TLR4 signaling in obese NAFLD. Am. J. Physiology. Gastrointest. Liver Physiol., 2015, Vol. 309, no. 4, pp. G270-278.</mixed-citation><mixed-citation xml:lang="en">Sharifnia T., Antoun J., Verriere T.G., Suarez G., Wattacheril J., Wilson K.T., Peek R.M. Jr, Abumrad N.N., Flynn C.R. Hepatic TLR4 signaling in obese NAFLD. Am. J. Physiology. Gastrointest. Liver Physiol., 2015, Vol. 309, no. 4, pp. G270-278.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sviriaeva E.N., Korneev K.V., Drutskaya M.S., Nedospasov S.A., Kuprash D.V. Modeling of viral-bacterial coinfections at the molecular level using agonists of innate immunity receptors. Dokl. Biochem. Biophys., 2016, Vol. 471, no. 1, pp. 393-395.</mixed-citation><mixed-citation xml:lang="en">Sviriaeva E.N., Korneev K.V., Drutskaya M.S., Nedospasov S.A., Kuprash D.V. Modeling of viral-bacterial coinfections at the molecular level using agonists of innate immunity receptors. Dokl. Biochem. Biophys., 2016, Vol. 471, no. 1, pp. 393-395.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
